Tianjin Zhong Xin Pharmaceutical Group Corporation Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tianjin Zhong Xin Pharmaceutical Group Corporation Limited with three other
companies in this sector in China:
Chongqing Taiji Industry (Group)
sales of 7.16 billion Chinese Renmimbi [US$1.04 billion]
of which 56%
Livzon Pharmaceutical Group Incorporated
(6.62 billion Chinese Renmimbi [US$959.05 million]
of which 39%
was Western Medicine), and
Sichuan Kelun Pharmaceutical Company Limited
(7.76 billion Chinese Renmimbi [US$1.12 billion]
of which 98%
was Medical and Pharmaceutical Products).
During the year ended December of 2015, sales at
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited were 7.08 billion Chinese Renmimbi (US$1.03 billion).
decrease of 0.1%
versus 2014, when the company's sales were 7.09 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 10.4% decline
in Western Medicine, from 2.41 billion Chinese Renmimbi to 2.16 billion Chinese Renmimbi.
However, these declines were partially offset by the increase in sales of
Chinese Medicine (up 4.7% to 4.36 billion Chinese Renmimbi)
Others (up 14.7% to 556.37 million Chinese Renmimbi)